RYTM
Rhythm Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$102.80
−2.00%Year over year
Reported trailing growth
- Revenue
- +53.5%
- EBITDA
- -15.7%
- EBIT
- -13.1%
- EPS
- -4.0%
- Free cash flow
- -39.7%
- Operating cash flow
- -38.8%
Forward estimates
Based on analyst estimates
- Revenue
- +70.6%
- EBITDA
- +26.4%
- EPS
- +22.2%
Three-year CAGR
- Revenue
- +100.2%
- EBITDA
- +26.9%
- EBIT
- +27.7%
- Net income
- +24.6%
- EPS
- +28.3%
- Free cash flow
- -2.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026